Overview

MitoQ for Fatigue in Multiple Sclerosis (MS)

Status:
Recruiting

Trial end date:
2023-11-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

VA Office of Research and Development

Treatments:

Ubiquinone